- KRAS - Wikipedia
In 2012, the FDA cleared a genetic test by QIAGEN named therascreen KRAS test, designed to detect the presence of seven mutations in the KRAS gene in colorectal cancer cells
- What’s new in KRAS mutation research? - MD Anderson Cancer Center
Cancer cells often develop genetic mutations that initiate and sustain the growth of tumors The most frequently mutated of these oncogenic driver genes, called KRAS, is associated with some of the most fatal cancer types: lung, pancreatic and colorectal cancers
- KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic . . .
Kristen rat sarcoma (KRAS) gene is one of the most common mutated oncogenes in solid tumors Yet, KRAS inhibitors did not follow suit with the development of targeted therapy, for the structure of KRAS has been considered as being implausible to target for decades
- KRAS mutation: from undruggable to druggable in cancer
In this review, the latest research progress on KRAS, the characteristics of KRAS mutations, the relationship between the KRAS mutations and tumour immunity, and the targeted research
- KRAS Mutations: Their Role in Cancer and Targeted Therapy
A mutation in the KRAS gene alters the K-Ras protein, causing it to become persistently active, or “stuck in the on position ” This continuous activation leads to uncontrolled cell growth and division, a hallmark of cancer
- Exploring KRAS: A precision approach in oncology - Merck. com
Several different mutations of KRAS have been identified, and commonly found types include G12C, G12V and G12D The KRAS G12C mutation occurs in approximately 14% of non-small cell lung cancer (NSCLC) and 3-5% of colorectal cancers “We now know there’s no one-size-fits-all approach to treating cancer
- KRAS Mutations in Cancer: Understanding Signaling Pathways to . . . - MDPI
KRAS mutations promote oncogenic signaling and modify the tumor microenvironment (TME), promoting immune evasion and tumor growth These alterations lead to treatment resistance, highlighting the importance of targeted therapies in KRAS-driven cancers
- KRAS gene: MedlinePlus Genetics
Several mutations in the KRAS gene have been identified in people with characteristic features of the disorder, which include heart defects, distinctive facial features, and skin abnormalities These mutations are present in all of the body's cells and are known as germline mutations
|